Dunn MCC, Knight DA, Waldman WJ (2011): Antiviral activity of leflunomide against respiratory syncytial virus in vivo. Antiviral Therapy 16: 309-317.
Nagy A, Harrison A, Sabbani S, Munson RS, Dutta PK, Waldman WJ (2011): Silver nanoparticles embedded in zeolite membranes: Release of silver ions and mechanisms of antimicrobial action. International Journal of Nanomedicine 6:1833-1852.Nagy A, Zane A, Cole S, Severance M, Dutta PK, Waldman WJ (2011): Contrast of the biological activity of negatively and positively charged microwave-synthesized CdSe/ZnS quantum dots. Chemical Research in Toxicology 24: 2176-2188. IF: 3.74
Waldman WJ, Bickerstaff A, Gordillo G, Orosz K, Knight DA, Orosz CG (2001): Inhibition of angiogenesis-related endothelial activity by the experimental immunosuppressive agent leflunomide. Transplantation 72:1578-1582.
Waldman WJ, LeClaire JD, Knight DA (2002): T cell activation response to allogeneic CMV-infected endothelial cells is not prevented by ganciclovir or foscarnet: Implications for transplant vascular sclerosis. Transplantation 73: 314-318.
Kristovich R, Knight DA, Long JF, Williams MV, Dutta PK, Waldman WJ (2004): Macrophage-mediated endothelial inflammatory responses to airborne particulates: Impact of particulate physicochemical properties. Chemical Research in Toxicology 17: 1303-1312.
Avery RK, Bolwell B, Yen-Lieberman B, Lurain N, Waldman WJ, Longworth DL, Taege AJ, Mossad SB, Kohn D, Long J, Curtis J, Kalaycio M, Pohlman B, Williams JW (2004): Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplantation 34: 1071-1075.
Chong AS, Zeng H, Knight DA, Shen J, Meister GT, Williams JW, Waldman WJ (2006): Concurrent antiviral and immunosuppressive activities of leflunomide in vivo. American Journal of Transplantation 6: 69-75.
Waldman WJ, Williams MV, Litsky ML, Lemeshow S, Binkley P, Guttridge D, Kiecolt-Glaser J, Knight DA, Ladner KJ, Glaser R (2008): Epstein Barr virus-encoded dUTPase enhances proinflammatory cytokine production by macrophages interacting with endothelial cells: Evidence for stress-induced atherosclerotic risk. Brain, Behavior and Immunity 22: 215-223.
The Waldman lab is currently engaged in active, funded research projects in the areas of antiviral drug discovery and environmental toxicology as summarized here.
Antiviral drug discovery and pre-clinical development: We have discovered that the anti-inflammatory, immunosuppressive drug, leflunomide, exerts potent antiviral activity against several clinically significant pathogenic viruses including cytomegalovirus (CMV), herpes simplex (HSV), polyomavirus BK (BKV), and respiratory syncytial virus (RSV). Unlike most antiviral drugs, leflunomide does not inhibit viral genomic nucleic acid synthesis. Rather it appears to target some other stage of the viral life cycle (in the case of CMV, phosphorylation of viral structural proteins and subsequent virion assembly). We are currently investigating molecular mechanisms underlying the antiviral activities of this agent, including the identification of cellular pathways which are perturbed by leflunomide and which may be essential in infectious virus production. In addition we continue to test this drug against other viruses.
Environmental toxicology: In collaboration with investigators in the OSU Department of Chemistry and at the National Institute of Occupational Safety and Health, we are studying the chemical and biological activity of airborne nanoparticulates, correlating cellular toxicity and inflammatory responses with specific physicochemical properties of the particulates. In addition we are investigating mechanisms of nanoparticulate cellular internalization and intracellular trafficking, as well as routes of particulate dissemination and sites of accumulation in vivo following inhalation exposure.